Hispanopedia Wiki
Articulo de referencia

Lys-MDA

Lys-MDA , or lysine-MDA , also known as N -( L -lysinamidyl)-MDA , is an entactogen of the phenethylamine , amphetamine , and MDxx families with entactogenic effects, which acts...

Hispanopedia WikiContenido en espanolLectura gratuita

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action.[1] Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[2][3][4][5] A phase 1clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.[1]

Interactions

See also

References

  1. 1234Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME (September 2025). "Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants". Neuropsychopharmacology. 51 (2): 476–485. doi:10.1038/s41386-025-02248-3. PMC 12708835. PMID 40999236.
  2. ↑Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
  3. ↑"MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
  4. ↑ WO 2022/053696 , Grill M, "Nuevos derivados de safrilamina con propiedades de profármaco.", publicado el 17 de marzo de 2022, asignado a Compass Pathfinder Limited. 
  5. ↑ WO 2023/283373 , Clark S, Duncton MA, "Metilendioximetanfetamina y psicodélicos relacionados y sus usos", publicado el 12 de enero de 2023, asignado a Terran Biosciences Inc. 
  6. ↑ "ClinicalTrials.gov" . ClinicalTrials.gov . 13 de agosto de 2024. Consultado el 13 de noviembre de 2024 .
  • Lisina-MDA (Lys-MDA) - Diseño de isómeros